IL-2 and Monoclonal Antibody - A never before used combination to be used in a human clinical trial to eliminate HIV
HIV could be eliminated using a novel combination of drugs, claims a research team on the brink of an unprecedented experiment. Scientists at Case Western Reserve University's medical school have been granted $2.5 million to try pairing two never-before-combined AIDS treatments in a human clinical trial.
'Administered alone, both Il-2 [interleukin-2] and certain monoclonal antibodies can reduce—but not necessarily eliminate— the presence of HIV in the body,' said Dr. Lederman. 'Our study will go the next step and use them together.' IL-2 is approved by the Food and Drug Administration for treating certain cancers. It activates killer cells and also activates HIV from latency (a positive development since the activated cells die when expressing virus). Monoclonal antibodies that neutralize HIV are cloned protein antibodies that bind to the surface of HIV and keep it from infecting the body's immune cells. They also can help killer cells attack HIV infected cells that have been activated from latency to express virus. The study is set to include 16 patients and begin in the second half of 2017. In the 64-week study, patients in one treatment group will receive IL-2 and those in a second treatment group will receive IL-2 plus a monoclonal antibody that neutralizes HIV.